Table 1 Demographic and clinical data of the patients
Parameter | No. of patients (%) |
|---|---|
Age, median (range) | 44 (18–64) |
Sex, male patients/female patients | 25 (56.8)/19 (43.2) |
Underlying disease | |
AML | 16 (36.3) |
Non-Hodgkin's lymphoma | 8 (18.1) |
Myelodysplastic syndrome | 7 (15.9) |
ALL | 3 (6.8) |
Plasma cell disorders | 3 (6.8) |
CLL | 2 (4.5) |
CML | 2 (4.5) |
Hodgkin's lymphoma | 2 (4.5) |
Aplastic anemia | 1 (2.3) |
Donor type | |
Matched unrelated | 22 (50.0) |
Mismatched unrelated | 22 (50.0) |
Conditioning regimen | |
Myeloablative | 29 (65.9) |
Myeloablative | 15 (34.1) |
Stem cell source | |
Peripheral blood | 29 (69.5) |
Umbilical cord blood | 14 (31.8) |
Bone marrow | 1 (2.3) |
ATG treatment | |
Yes | 28 (63.6) |
No | 16 (36.4) |
Acute GVHD | |
Grades 0 and I | 31 (70.4) |
Grades II–IV | 13 (29.6) |
Active CMV infection pre-emptively treated a | |
Yes | 35 (79.5) |
No | 9 (20.5) |
CMV end-organ disease b | |
Yes | 3 (6.8) |
No | 41 (93.2) |
